This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk: Results From the PARTNER 2 Trial

Tuesday, December 18, 2018

Submitted by



Suzanne J. Baron, Kaijun Wang, John A. House, Elizabeth A. Magnuson, Matthew R. Reynolds, Raj Makkar, Howard C. Herrmann, Susheel Kodali, Vinod H. Thourani, Samir Kapadia, Lars Svensson, Michael J. Mack, David L. Brown, Mark J. Russo, Craig R. Smith, John Webb, Craig Miller, Martin B. Leon , David J. Cohen, and on behalf of the PARTNER 2 Investigators

This study analyzed the cost-effectiveness of TAVR versus SAVR in 3110 intermediate-risk aortic stenosis patients from the PARTNER-2 trial. Using a Markov model, the authors found that TAVR is economically dominant from the perspective of lifetime cost-effectiveness in the US healthcare system. TAVR was estimated to save $8,000-$10,000 over the lifetime of the patient and to increase quality-adjusted survival by 0.15-0.27 years.

Add comment

Log in or register to post comments